Skip Nav Destination
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study
Issue Archive
August 23 2012
In this Issue
Table of Contents
Inside Blood
Blood Work
Perspectives
Review Article
How I Treat
Clinical Trials and Observations
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
CME
Harry J. Iland,for the Australasian Leukaemia and Lymphoma Group,Ken Bradstock,for the Australasian Leukaemia and Lymphoma Group,Shane G. Supple,for the Australasian Leukaemia and Lymphoma Group,Alberto Catalano,for the Australasian Leukaemia and Lymphoma Group,Marnie Collins,for the Australasian Leukaemia and Lymphoma Group,Mark Hertzberg,for the Australasian Leukaemia and Lymphoma Group,Peter Browett,for the Australasian Leukaemia and Lymphoma Group,Andrew Grigg,for the Australasian Leukaemia and Lymphoma Group,Frank Firkin,for the Australasian Leukaemia and Lymphoma Group,Amanda Hugman,for the Australasian Leukaemia and Lymphoma Group,John Reynolds,for the Australasian Leukaemia and Lymphoma Group,Juliana Di Iulio,for the Australasian Leukaemia and Lymphoma Group,Campbell Tiley,for the Australasian Leukaemia and Lymphoma Group,Kerry Taylor,for the Australasian Leukaemia and Lymphoma Group,Robin Filshie,for the Australasian Leukaemia and Lymphoma Group,Michael Seldon,for the Australasian Leukaemia and Lymphoma Group,John Taper,for the Australasian Leukaemia and Lymphoma Group,Jeff Szer,for the Australasian Leukaemia and Lymphoma Group,John Moore,for the Australasian Leukaemia and Lymphoma Group,John Bashford,for the Australasian Leukaemia and Lymphoma Group,John F. Seymour,for the Australasian Leukaemia and Lymphoma Group
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
Clinical Trials & Observations
Michael R. Loken,Todd A. Alonzo,Laura Pardo,Robert B. Gerbing,Susana C. Raimondi,Betsy A. Hirsch,Phoenix A. Ho,Janet Franklin,Todd M. Cooper,Alan S. Gamis,Soheil Meshinchi
Hematopoiesis and Stem Cells
Immunobiology
Deletion of cognate CD8 T cells by immature dendritic cells: a novel role for perforin, granzyme A, TREM-1, and TLR7
Lior Zangi,Yael Zlotnikov Klionsky,Liran Yarimi,Esther Bachar-Lustig,Yaki Eidelstein,Elias Shezen,David Hagin,Yumi Ito,Toshiyuki Takai,Shlomit Reich-Zeliger,Assaf Lask,Oren Milstein,Steffen Jung,Vera Shinder,Yair Reisner
Lymphoid Neoplasia
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Clinical Trials & Observations
Laura Rosiñol,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Albert Oriol,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Ana Isabel Teruel,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Dolores Hernández,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Javier López-Jiménez,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Javier de la Rubia,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Miquel Granell,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Joan Besalduch,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Luis Palomera,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Yolanda González,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Mª Asunción Etxebeste,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Joaquín Díaz-Mediavilla,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Miguel T. Hernández,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Felipe de Arriba,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Norma C. Gutiérrez,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Mª Luisa Martín-Ramos,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Mª Teresa Cibeira,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Mª Victoria Mateos,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Joaquín Martínez,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Adrián Alegre,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Juan José Lahuerta,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Jesús San Miguel,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group,Joan Bladé,on behalf of the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
Clinical Trials & Observations
Saad Z. Usmani,Rachel Sexton,Antje Hoering,Christoph J. Heuck,Bijay Nair,Sarah Waheed,Yazan Al Sayed,Nabeel Chauhan,Nisar Ahmad,Shebli Atrash,Nathan Petty,Frits van Rhee,John Crowley,Bart Barlogie
LNA-mediated anti–miR-155 silencing in low-grade B-cell lymphomas
Yong Zhang,Aldo M. Roccaro,Christopher Rombaoa,Ludmilla Flores,Susanna Obad,Stacey M. Fernandes,Antonio Sacco,Yang Liu,Hai Ngo,Phong Quang,Abdel Kareem Azab,Feda Azab,Patricia Maiso,Michaela Reagan,Jennifer R. Brown,To-Ha Thai,Sakari Kauppinen,Irene M. Ghobrial
Myeloid Neoplasia
SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control
Pavankumar N. G. Reddy,on behalf of the Study Alliance Leukemia (SAL),Bülent Sargin,on behalf of the Study Alliance Leukemia (SAL),Chunaram Choudhary,on behalf of the Study Alliance Leukemia (SAL),Stefan Stein,on behalf of the Study Alliance Leukemia (SAL),Manuel Grez,on behalf of the Study Alliance Leukemia (SAL),Carsten Müller-Tidow,on behalf of the Study Alliance Leukemia (SAL),Wolfgang E. Berdel,on behalf of the Study Alliance Leukemia (SAL),Hubert Serve,on behalf of the Study Alliance Leukemia (SAL),Christian H. Brandts,on behalf of the Study Alliance Leukemia (SAL)
Phagocytes, Granulocytes, and Myelopoiesis
Platelets and Thrombopoiesis
Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor α
Marie-Cécile Valéra,Marie-Pierre Gratacap,Pierre Gourdy,Françoise Lenfant,Cendrine Cabou,Celine E. Toutain,Marlene Marcellin,Nathalie Saint Laurent,Pierre Sié,Michel Sixou,Jean-François Arnal,Bernard Payrastre
Thrombosis and Hemostasis
Transplantation
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study
Clinical Trials & Observations
Takashi Ishida,Masakatsu Hishizawa,Koji Kato,Ryuji Tanosaki,Takahiro Fukuda,Shuichi Taniguchi,Tetsuya Eto,Yoshifusa Takatsuka,Yasushi Miyazaki,Yukiyoshi Moriuchi,Michihiro Hidaka,Koichi Akashi,Naokuni Uike,Hisashi Sakamaki,Yasuo Morishima,Koji Kato,Ritsuro Suzuki,Takeshi Nishiyama,Atae Utsunomiya
Other Departments
-
Cover Image
Cover Image
The combination of all-trans-retinoic acid (ATRA) and arsenic trioxide used during induction and consolidation with minimal idarubicin yielded a remarkable 2-year event-free survival rate of 98% and early death rate of 3.2%. This is one of the best outcomes observed in acute promyelocytic leukemia (APL) studies. Professional illustration by Noel Sirivansanti/Xavier Studio. See the article by Iland et al on page 1570.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals